Cohort of HIV-infected patients who began treatment with protease inhibitor in 1997-1999. Follow-up over 4 years on the long-term effects linked with adherence and tolerance (COPILOT).

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Patients included in the APROCO cohort (adults infected with HIV-1 at first prescription of protease inhibitor in 1997-99), monitored for four years in APROCO after initial enrolment, monitored by voluntary services in order to participate in extended follow-up, having given their written consent.","clusion_E":""}